Revenue growth has collapsed, evidenced by a 47.2% year-over-year decline in 2026Q1, while gross margins have eroded significantly from 78.1% in 2023Q4 to 41.7% in the most recent quarter.
| Sales/Revenue | 12.6M | 15.23M | 32.11M | 53.47M | 64.21M | 38.24M | 0 |
| Revenue Growth % | -55.49% | -52.57% | -39.94% | -16.73% | 67.91% | - | - |
| Cost of Goods Sold | 5.96M | 5.66M | 10.61M | 11.97M | 13.48M | 9.05M | 0 |
| COGS % of Revenue | - | 37.16% | 33.03% | 22.39% | 21% | 23.67% | - |
| Gross Profit | 6.64M | 9.57M | 21.5M | 41.5M | 50.73M | 29.19M | 0 |
| Gross Margin % | 52.7% | 62.84% | 66.97% | 77.61% | 79% | 76.33% | - |
| Gross Profit Growth % | - | -55.49% | -48.18% | -18.19% | 73.78% | - | - |
| Operating Expenses | 33.24M | 39.73M | 71.7M | 120.58M | 82.74M | 41.69M | 5.17K |
| OpEx % of Revenue | - | 260.85% | 223.3% | 225.51% | 128.85% | 109.02% | - |
| Selling, General & Admin | 27.39M | 32.16M | 54.33M | 92.88M | 65.77M | 35.96M | 4.56K |
| SG&A % of Revenue | - | 211.14% | 169.21% | 173.72% | 102.43% | 94.04% | - |
| Research & Development | 5.86M | 7.57M | 17.37M | 27.69M | 16.97M | 5.73M | 0 |
| R&D % of Revenue | - | 49.71% | 54.09% | 51.8% | 26.42% | 14.98% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 610 |
| Operating Income | -26.61M | -30.16M | -50.2M | -79.08M | -32.01M | -12.5M | -5.17K |
| Operating Margin % | -211.21% | -198.01% | -156.33% | -147.9% | -49.85% | -32.69% | - |
| Operating Income Growth % | - | 39.92% | 36.52% | -147.04% | -156.06% | -241745.62% | - |
| EBITDA | -25.66M | -29.17M | -49.2M | -78.33M | -31.11M | -11.79M | 201.13K |
| EBITDA Margin % | -203.66% | -191.56% | -153.23% | -146.51% | -48.46% | -30.84% | - |
| EBITDA Growth % | 43.31% | 40.7% | 37.19% | -151.75% | -163.82% | -5963.93% | - |
| D&A (Non-Cash Add-back) | 951K | 983K | 997K | 746K | 895K | 707K | 206.3K |
| EBIT | -39.89M | -28.68M | -23.17M | -69.78M | -33.17M | -8.72M | -5.17K |
| Net Interest Income | -1.82M | 0 | -2.26M | -10.57M | -4.43M | -3.67M | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.82M | 0 | 2.26M | 10.57M | 4.43M | 3.67M | 0 |
| Other Income/Expense | -6.74M | 1.48M | 24.77M | -1.26M | -5.59M | 115K | 0 |
| Pretax Income | -33.35M | -28.68M | -25.43M | -80.34M | -37.6M | -12.39M | -5.17K |
| Pretax Margin % | -264.73% | -188.32% | -79.2% | -150.27% | -58.56% | -32.39% | - |
| Income Tax | 1K | 74K | 718K | 264K | 143K | 0 | 0 |
| Effective Tax Rate % | -0% | -0.26% | -2.82% | -0.33% | -0.38% | 0% | 0% |
| Net Income | -33.35M | -28.75M | -26.15M | -80.61M | -37.74M | -12.39M | -5.17K |
| Net Margin % | -264.74% | -188.81% | -81.43% | -150.76% | -58.78% | -32.39% | - |
| Net Income Growth % | 15.35% | -9.97% | 67.56% | -113.56% | -204.73% | -239520.82% | - |
| Net Income (Continuing) | -33.35M | -28.75M | -26.15M | -80.61M | -37.74M | -12.39M | -5.17K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -37.47 | -57.15 | -48.00 | -890.70 | -566.25 | 20.10 | -0.02 |
| EPS Growth % | 31.14% | -19.06% | 94.61% | -57.3% | -2917.16% | 111766.67% | - |
| EPS (Basic) | - | -57.15 | -48.00 | -890.70 | -566.25 | 20.10 | -0.02 |
| Diluted Shares Outstanding | 890.04K | 502.97K | 149.81K | 94.89K | 71.78K | 287.5K | 287.5K |
| Basic Shares Outstanding | 890.04K | 502.97K | 149.81K | 94.89K | 71.78K | 287.5K | 287.5K |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
Insufficient liquidity for operations
As reported in recent financial filings, Allurion's revenue has experienced a severe downturn, with the most recent quarter showing a 47.2% year-over-year decline, signaling a fundamental breakdown in the company's volume-driven growth model as it struggles to compete against the rapid adoption of GLP-1 pharmaceutical alternatives.
The consistent double-digit revenue contraction suggests that the company's core balloon technology is losing market relevance or facing significant pricing pressure. Investors should monitor whether this trend reflects a permanent shift in patient preference toward pharmacological weight-loss solutions rather than mechanical interventions.
Based on the company's historical income statements, gross margins have demonstrated significant instability, falling from a peak of 78.1% in late 2023 to 41.7% in the most recent quarter, which indicates a potential loss of pricing power or rising costs associated with manufacturing and distribution.
The compression of gross margins is particularly concerning given the company's need to maintain high margins to offset its heavy operating expenses. This volatility suggests that the firm may be forced to offer deeper discounts to maintain volume, further straining its already limited financial resources.
According to the provided income statement data, Allurion's operating margin reached -126.6% in the latest quarter, illustrating that the company's fixed cost structure remains entirely unscaled relative to its current revenue base, resulting in a persistent and widening gap between gross profit and operating expenses.
The inability to achieve operating leverage suggests that the current sales and marketing infrastructure is not yielding sufficient returns on investment. Without a dramatic increase in unit volume, the company appears trapped in a cycle where fixed costs continue to consume the majority of its gross profit.
Data from recent quarterly reports indicates that with operating margins consistently in the triple digits and a cash balance of only $5.4 million, the company faces a critical liquidity risk that may necessitate highly dilutive financing or a strategic exit to avoid a total depletion of capital.
Short-sellers would likely focus on the widening disconnect between the company's digital health narrative and its actual financial performance. The lack of a clear path to profitability suggests that the current business model may be unsustainable without a fundamental restructuring of its cost base or a pivot in its commercial strategy.
Quick answers to the most common questions about buying ALUR stock.
For fiscal year 2025, Allurion Technologies Inc. (ALUR) reported total revenue of $15.2M.
Allurion Technologies Inc. (ALUR) reported a net loss of $28.8M for the fiscal year ending 2025.
Allurion Technologies Inc. (ALUR) reported an operating income of $-30.2M, resulting in an operating profit margin of -198.0%. This margin reflects the operational efficiency of the business before interest and taxes.
Allurion Technologies Inc. (ALUR) generated $9.6M in gross profit for the year, representing a gross profit margin of 62.8%. This demonstrates the company's core pricing power and production efficiency.